AstraZeneca Full year and Q4 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
AstraZeneca's earnings top estimates but shares fall on core operating profit drop
February 8, 2024 6:41 AM ESTAstraZeneca (NASDAQ: AZN) shares fell more than 6% in premarket trading Thursday after the drugmaker reported notably lower-than-expected core operating profit for the fourth quarter.
Earnings per share (EPS) came in at $1.45 in Q4, topping the forecasted $0.74. The pharmaceutical giant generated a quarterly revenue of $12.02 billion, also above the consensus estimate of $12 billion.
Core operating profit rose 5.4% year-over-year to $2.75 billion, but was... More
Deutsche Bank Downgrades AstraZeneca (AZN) to Hold
February 8, 2024 5:37 AM ESTDeutsche Bank analyst Emmanuel Papadakis downgraded AstraZeneca (NASDAQ: AZN) from Buy to Hold.
The analyst comments "Q4 is a thoroughly underwhelming end to 2023 with a soft print that missed in most of the places that matter (Enhertu included, again), whilst FY24 guidance is... More
